



ICoLA 2019

The 8th International Congress on Lipid & Atherosclerosis (ICoLA)

The 58th Conference of the Korean Society of Lipid & Atherosclerosis

September 5(Thu.) ~ 7(Sat.), 2019, Conrad Hotel Seoul, Republic of Korea

Current and Future Lipid Treatment through Recent Key Outcomes

Anselm K. Gitt, MD, FESC, FACC

Herzzentrum Ludwigshafen, Dep. of Cardiology, Germany

Gitta@klilu.de

Abstract

Cardiovascular disease (CVD) has been rapidly increasing. It is one of the leading cause of death in World. Although LDL-C treatment is a primary and major risk factor of CVD and very important for preventing CVD, we are still facing treatment gap with traditional statin treatment. Since IMPROVE-IT Trial had been presented in 2014, adding non-statin therapy had been recommended for LDL-C lowering strategy. Recently various non-statin agents have been shown evidences for CVD prevention.

This lecture will summarize the overall outcomes of non-statin agents, recent treatment guideline for the management of dyslipidemia and suggest how we well manage LDL-C in real world with ezetimibe/atorvastatin FDCs.